EMS Unveils New Injector Pens for Diabetes and Obesity Treatment
Brazilian pharmaceutical company EMS announced the release of Olire and Lirux injector pens for obesity and type 2 diabetes, respectively. Made locally, the pens utilize liraglutide similar to Saxenda. The launch sets the stage for EMS's entry into semaglutide medications post-Ozempic's patent expiration in Brazil next year.
Brazilian pharmaceutical giant EMS has announced that its latest product, injector pens aimed at treating diabetes and obesity, will hit local pharmacy shelves on August 4. Named Olire and Lirux, these pens are expected to significantly aid in the management of these widespread health issues.
Both injector pens, produced in Brazil, contain liraglutide, the same active ingredient used in Saxenda from Novo Nordisk. Liraglutide has shown continuous success in controlling blood glucose levels and weight, aligning it with Nordisk's widely known Ozempic.
A total of 100,000 units of Olire, meant for obesity treatment, and 50,000 units of Lirux, intended for type 2 diabetes control, will be available at select Brazilian pharmacy chains. This launch positions EMS and competitors like Hypera Pharma to introduce semaglutide medications next year, aligning with the anticipated expiration of Ozempic's patent in March.
(With inputs from agencies.)
Google News